

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# ETHK<sup>®</sup> Labs

## 华检医疗 (1931.HK)

**ETHK Labs Inc.**

**華檢醫療控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1931)**

### ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025

The board (the “**Board**”) of directors (the “**Directors**”) of ETHK Labs Inc. (formerly known as “IVD Medical Holding Limited”) (the “**Company**”) is pleased to announce the financial results of the Company and its subsidiaries (collectively, the “**Group**”) for the year ended 31 December 2025 (the “**Reporting Period**”) as below.

#### FINANCIAL HIGHLIGHTS

	<b>2025</b>	2024	Change
	<b>RMB’000</b>	RMB’000	
Revenue	<b>2,820,663</b>	3,162,415	(10.8%)
Gross profit	<b>566,370</b>	751,173	(24.6%)
Profit for the year	<b>37,406</b>	266,034	(85.9%)
Profit attributable to owners of the parent	<b>34,933</b>	260,420	(86.6%)
Adjusted profit for the year <i>(Note)</i>	<b>52,409</b>	280,413	(81.3%)
Adjusted profit attributable to owners of the parent <i>(Note)</i>	<b>49,679</b>	274,246	(81.9%)
<b>Earnings per share</b>			
Basic (RMB cents)	<b>2.16</b>	17.42	(87.6%)
Diluted (RMB cents)	<b>2.16</b>	17.42	(87.6%)

*Note:* Adjusted profit for the year and adjusted profit attributable to owners of the parent are non-GAAP financial measures. They are calculated by excluding certain impact of non-operating items which affect the results presented in the consolidated financial statements but which the Company considers them to be not indicative of the operating performance of the Group, and are included with the intent to provide shareholders of the Company (“**Shareholders**”) and potential investors with supplementary information to assess the performance of the Group’s core operations. See the paragraph headed “Adjusted profit for the year” in this announcement for more information about these measures.

For the Reporting Period, the Group achieved revenue of RMB2,820,663 thousand, which represented a decrease of 10.8% as compared to the year ended 31 December 2024. Such decrease was primarily attributable to a more competitive operating environment in the IVD industry.

Profit of the Group for the Reporting Period recorded a decrease of 85.9% as compared to the year ended 31 December 2024. Such decrease was attributable to (i) primarily the impact of a more competitive operating environment in the IVD industry; (ii) an increase in administrative expenses incurred from the Group's newly launched AI business; and (iii) an increase in finance costs due to the increase in Group's borrowings to support its business expansion and working capital requirements, resulting in additional interest expenses.

The Board did not recommended a final dividend in respect of 2025.

**CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER  
COMPREHENSIVE INCOME**

*Year ended 31 December 2025*

	<i>Notes</i>	<b>2025</b> <b>RMB'000</b>	2024 <i>RMB'000</i>
<b>Revenue</b>	4	<b>2,820,663</b>	3,162,415
Cost of sales		<u><b>(2,254,293)</b></u>	<u>(2,411,242)</u>
<b>Gross profit</b>		<b>566,370</b>	751,173
Other income and (losses) gains, net	5	<b>(5,203)</b>	21,813
Selling and distribution expenses		<b>(159,548)</b>	(139,805)
Administrative expenses		<b>(220,912)</b>	(165,332)
Impairment losses of trade and other receivables, net		<b>(5,606)</b>	(1,796)
Finance costs	6	<b>(60,687)</b>	(35,979)
Fair value loss on financial assets at fair value through profit or loss		<b>(11,264)</b>	(9,468)
Share of losses of associates		<b>(9,468)</b>	(10,217)
Share of loss of a joint venture		<u><b>(5,450)</b></u>	<u>(8,612)</u>
<b>Profit before tax</b>	7	<b>88,232</b>	401,777
Income tax expense	8	<u><b>(50,826)</b></u>	<u>(135,743)</u>
<b>Profit for the year</b>		<u><b>37,406</b></u>	<u>266,034</u>
<b>Profit for the year attributable to:</b>			
Owners of the parent		<b>34,933</b>	260,420
Non-controlling interests		<u><b>2,473</b></u>	<u>5,614</u>
<b>Profit for the year</b>		<u><b>37,406</b></u>	<u>266,034</u>

	<i>Note</i>	<b>2025</b> <b>RMB'000</b>	2024 RMB'000
<b>OTHER COMPREHENSIVE (LOSS) INCOME</b>			
<b>Other comprehensive (loss) income that may be reclassified to profit or loss in subsequent periods:</b>			
Exchange differences on translation of foreign operations, net		<u>(5,061)</u>	<u>756</u>
		<b>(5,061)</b>	<b>756</b>
<b>Other comprehensive income that will not be reclassified to profit or loss in subsequent periods:</b>			
Exchange differences on translation of the Company's financial statements, net		<u>3,043</u>	<u>12,127</u>
<b>Other comprehensive (loss) income for the year, net of tax</b>		<u><b>(2,018)</b></u>	<u><b>12,883</b></u>
<b>Total comprehensive income for the year</b>		<u><b>35,388</b></u>	<u><b>278,917</b></u>
<b>Total comprehensive income attributable to:</b>			
Owners of the parent		<u>32,915</u>	<u>273,303</u>
Non-controlling interests		<u>2,473</u>	<u>5,614</u>
		<u><b>35,388</b></u>	<u><b>278,917</b></u>
<b>Earnings per share attributable to ordinary equity holders of the parent</b>			
	<i>10</i>		
Basic (RMB cents)		<u>2.16</u>	<u>17.42</u>
Diluted (RMB cents)		<u>2.16</u>	<u>17.42</u>

## CONSOLIDATED STATEMENT OF FINANCIAL POSITION

31 December 2025

	<i>Notes</i>	<b>2025</b> <b>RMB'000</b>	2024 <i>RMB'000</i>
<b>NON-CURRENT ASSETS</b>			
Property, plant and equipment		<b>204,818</b>	104,312
Intangible assets		<b>1,635,885</b>	1,635,885
Investments in associates		<b>480,596</b>	10,806
Investment in a joint venture		<b>20,214</b>	25,167
Financial assets at fair value through profit or loss		<b>2,427</b>	16,011
Deferred tax assets		<b>23,994</b>	15,065
		<hr/>	<hr/>
Total non-current assets		<b>2,367,934</b>	1,807,246
<b>CURRENT ASSETS</b>			
Inventories		<b>2,287,967</b>	1,236,751
Trade receivables	<i>11</i>	<b>452,554</b>	484,276
Prepayments and other receivables		<b>275,944</b>	137,875
Financial assets at fair value through profit or loss		<b>2,136</b>	–
Pledged deposits		<b>197,758</b>	83,378
Cash and cash equivalents		<b>350,924</b>	1,774,358
		<hr/>	<hr/>
Total current assets		<b>3,567,283</b>	3,716,638
<b>CURRENT LIABILITIES</b>			
Trade payables	<i>12</i>	<b>656,213</b>	595,183
Other payables and accruals	<i>13</i>	<b>141,267</b>	188,311
Interest-bearing bank borrowings		<b>1,842,042</b>	732,566
Tax payable		<b>13,997</b>	30,609
		<hr/>	<hr/>
Total current liabilities		<b>2,653,519</b>	1,546,669
<b>NET CURRENT ASSETS</b>		<b>913,764</b>	2,169,969
		<hr/>	<hr/>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		<b>3,281,698</b>	3,977,215
		<hr/>	<hr/>

	<i>Notes</i>	<b>2025</b> <b>RMB'000</b>	2024 <i>RMB'000</i>
<b>NON-CURRENT LIABILITIES</b>			
Other payables and accruals	<i>13</i>	<b>65,400</b>	13,167
Deferred tax liabilities		<b>204,941</b>	202,862
<b>Total non-current liabilities</b>		<b>270,341</b>	216,029
Net assets		<b>3,011,357</b>	3,761,186
<b>EQUITY</b>			
<b>Equity attributable to owners of the parent</b>			
Share capital	<i>14</i>	<b>5,589</b>	5,603
Reserves		<b>2,942,111</b>	3,709,015
		<b>2,947,700</b>	3,714,618
<b>Non-controlling interests</b>		<b>63,657</b>	46,568
<b>Total equity</b>		<b>3,011,357</b>	3,761,186

## NOTES TO FINANCIAL INFORMATION

### 1. CORPORATE INFORMATION

The Company is a company incorporated in the Cayman Islands with limited liability. The registered office of the Company is located at the office of Conyers Trust Company (Cayman) Limited, Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman KY1-1111, Cayman Islands. The principal place of business of the Company is located at Room 1703, Grandtech Centre, 8 On Ping Street, Shatin, Hong Kong. The shares of the Company commenced listing on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) on 12 July 2019 (the “**Listing**”).

The Company is an investment holding company. During the year, the Company’s subsidiaries were principally engaged in the sale and manufacture of medical equipment and consumables and provision of after-sales services related to medical equipment.

### 2.1 BASIS OF PREPARATION

The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“**IFRS**”) as issued by International Accounting Standards Board (the “**IASB**”) and the disclosure requirements of the Hong Kong Companies Ordinance. They have been prepared under the historical cost convention, except for financial assets at fair value through profit or loss which have measured at fair value. The consolidated financial statements are presented in Renminbi (“**RMB**”) and all values are rounded to the nearest thousand except when otherwise indicated.

#### **Basis of consolidation**

The consolidated financial statements include the financial statements of the Company and its subsidiaries (collectively referred to as the “**Group**”) for the year ended 31 December 2025. A subsidiary is an entity (including a structured entity), directly or indirectly, controlled by the Company. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee (i.e., existing rights that give the Group the current ability to direct the relevant activities of the investee).

Generally, there is a presumption that a majority of voting rights results in control. When the Company has less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including:

- (a) the contractual arrangement with the other vote holders of the investee;
- (b) rights arising from other contractual arrangements; and
- (c) the Group’s voting rights and potential voting rights.

The financial statements of the subsidiaries are prepared for the same reporting period as the Company, using consistent accounting policies. The results of subsidiaries are consolidated from the date on which the Group obtains control, and continue to be consolidated until the date that such control ceases.

Profit or loss and each component of other comprehensive income are attributed to the owners of the parent of the Group and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

The Group reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control described above. A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction.

If the Group loses control over a subsidiary, it derecognises the related assets (including goodwill), liabilities, any non-controlling interest and the exchange fluctuation reserve; and recognises the fair value of any investment retained and any resulting surplus or deficit in profit or loss. The Group's share of components previously recognised in other comprehensive income is reclassified to profit or loss or retained profits, as appropriate, on the same basis as would be required if the Group had directly disposed of the related assets or liabilities.

## **2.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES**

The Group has adopted amendments to IAS 21 Lack of Exchangeability for the first time for the current year's financial statements. The Group has not early adopted any other standard or amendment that has been issued but is not yet effective.

Amendments to IAS 21 specify how an entity shall assess whether a currency is exchangeable into another currency and how it shall estimate a spot exchange rate at a measurement date when exchangeability is lacking. The amendments require disclosures of information that enable users of financial statements to understand the impact of a currency not being exchangeable. As the currencies that the Group had transacted in and the functional currencies of overseas subsidiaries, joint ventures and associates for translation into the Group's presentation currency were exchangeable, the amendments did not have any impact on the Group's financial statements.

### 3. OPERATING SEGMENT INFORMATION

The Group is principally engaged in the sale and manufacture of medical equipment and consumables and the provision of after-sales services related to medical equipment. For the purpose of resource allocation and performance assessment, the Group's management focuses on the operating results of the Group. As such, the Group's resources are integrated and no discrete operating segment information is available. Accordingly, no operating segment information is presented.

#### Geographical information

##### (a) Revenue from external customers

	2025 <i>RMB'000</i>	2024 <i>RMB'000</i>
Chinese Mainland	2,812,848	3,154,904
Others	7,815	7,511
	<u>2,820,663</u>	<u>3,162,415</u>
Total revenue	<u>2,820,663</u>	<u>3,162,415</u>

The revenue information above is based on the locations of the customers.

##### (b) Non-current assets

	2025 <i>RMB'000</i>	2024 <i>RMB'000</i>
Chinese Mainland	2,303,212	1,769,684
Others	38,301	6,486
	<u>2,341,513</u>	<u>1,776,170</u>
Total non-current assets	<u>2,341,513</u>	<u>1,776,170</u>

The non-current asset information above is based on the locations of the assets and excludes financial instruments and deferred tax assets.

#### Information about major customers

During the years ended 31 December 2025 and 2024, no revenue from transactions with a single external customer amounted for 10% or more of the total revenue of the Group.

#### 4. REVENUE

An analysis of revenue is as follows:

	2025 <i>RMB'000</i>	2024 <i>RMB'000</i>
<i>Revenue from contracts with customers</i>		
Sales of trading goods	2,638,797	2,946,782
Sales of manufactured goods	9,323	9,644
Provision of after-sales services	172,543	205,989
	<u>2,820,663</u>	<u>3,162,415</u>

#### 5. OTHER INCOME AND (LOSSES) GAINS, NET

	2025 <i>RMB'000</i>	2024 <i>RMB'000</i>
<b>Other income</b>		
Bank interest income	1,830	2,672
Rental income	95	350
Government subsidies*	19,659	15,524
Others	9,374	1,635
	<u>30,958</u>	<u>20,181</u>
<b>Gains or losses</b>		
Written-off of prepayments	348	(143)
Gain (loss) on termination/modification of lease contracts	336	(66)
Gain on disposal of items of property, plant and equipment, net	29	47
Foreign exchange differences, net	(36,874)	1,794
	<u>(36,161)</u>	<u>1,632</u>
Total (losses) gains, net	<u>(36,161)</u>	<u>1,632</u>
Total other income and (losses) gains, net	<u>(5,203)</u>	<u>21,813</u>

\* Government grants have been received from the PRC local government authorities to support subsidiaries' daily operating activities. There are no unfulfilled conditions or contingencies relating to these grants.

## 6. FINANCE COSTS

An analysis of finance costs is as follows:

	<b>2025</b> <b>RMB'000</b>	2024 <i>RMB'000</i>
Interest on bank loans	<b>56,931</b>	26,883
Interest on lease liabilities	<b>2,437</b>	1,050
Interest on factored trade receivables	<b>1,319</b>	8,046
	<hr/>	<hr/>
Total finance costs	<b>60,687</b>	35,979
	<hr/> <hr/>	<hr/> <hr/>

## 7. PROFIT BEFORE TAX

The Group's profit before tax is arrived at after charging/(crediting):

	<b>2025</b> <b>RMB'000</b>	2024 <i>RMB'000</i>
Cost of inventories sold	<b>2,160,830</b>	2,321,961
Cost of services provided	<b>93,463</b>	89,281
Depreciation of owned assets	<b>26,978</b>	22,910
Depreciation of right-of-use assets	<b>27,811</b>	15,290
Research and development costs	<b>13,317</b>	7,402
Expenses relating to short term leases	<b>10,577</b>	7,207
Auditors' remuneration	<b>3,400</b>	3,400
Employee benefit expenses (including directors' and chief executive's remuneration):		
Wages and salaries	<b>177,979</b>	183,798
Pension scheme contributions	<b>43,751</b>	37,895
	<hr/>	<hr/>
Total	<b>221,730</b>	221,693
	<hr/>	<hr/>
Foreign exchange differences, net	<b>36,874</b>	(1,794)
Impairment losses of trade receivables, net	<b>5,477</b>	1,796
Impairment losses of other receivables	<b>129</b>	–
Write-down of inventories to net realisable value	<b>811</b>	3,658
	<hr/> <hr/>	<hr/> <hr/>

## 8. INCOME TAX EXPENSE

Hong Kong profits tax has been provided at the rate of 16.5% (2024: 16.5%) on the estimated assessable profits arising in Hong Kong during the year except for one subsidiary of the Group which is a qualifying entity under the two-tiered profits tax rates regime. The first HK\$2,000,000 (2024: HK\$2,000,000) of assessable profits of this subsidiary are taxed at 8.25% (2024: 8.25%) and the remaining assessable profits are taxed at 16.5% (2024: 16.5%). Tax on profits assessable in Chinese Mainland has been calculated at the applicable PRC corporate income tax (“CIT”) rate of 25% during the year.

	2025 <i>RMB'000</i>	2024 <i>RMB'000</i>
Current – Hong Kong profits tax		
Under-provision in prior years	1,996	–
Charge for the year	8,005	1,615
Current – Chinese Mainland		
Under-provision/(over-provision) in prior years	22	(1,621)
Charge for the year	47,653	127,774
Deferred	<u>(6,850)</u>	<u>7,975</u>
Total tax charge for the year	<u><u>50,826</u></u>	<u><u>135,743</u></u>

## 9. DIVIDENDS

No dividend was proposed for the year ended 31 December 2025, nor has any dividend been proposed since the end of the reporting period.

## 10. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic earnings per share amount is based on the profit for the year attributable to owners of the parent, and the weighted average number of ordinary shares in issue during the year.

The calculation of the diluted earnings per share amount is based on the profit for the year attributable to owners of the parent.

The weighted average number of ordinary shares used in the calculation is the number of ordinary shares in issue during the year ended 31 December 2025, as used in the basic earnings per share calculation, and the weighted average number of ordinary shares assumed to have been issued at no consideration on the deemed exercise or conversion of all dilutive potential ordinary shares into ordinary shares.

The Group had no potentially dilutive ordinary shares in issue during the year ended 31 December 2025.

The calculations of the basic and diluted earnings per share are based on:

	<b>2025</b>	2024
	<b>RMB'000</b>	RMB'000
<b>Earnings</b>		
Profit attributable to ordinary equity holders of the parent used in the basic earnings per share calculation	<u><b>34,933</b></u>	<u>260,420</u>
	<b>Number of shares</b>	
	<b>2025</b>	2024
<b>Shares</b>		
Weighted average number of ordinary shares in issue less shares held for Share Award Scheme held by the Company during the year used in the basic earnings per share calculation	<u><b>1,620,409,496</b></u>	<u>1,495,230,580</u>

## 11. TRADE RECEIVABLES

	<b>2025</b>	2024
	<b>RMB'000</b>	RMB'000
Trade receivables	<b>463,365</b>	489,779
Impairment	<u><b>(10,811)</b></u>	<u>(5,503)</u>
Net carrying amount	<u><b>452,554</b></u>	<u>484,276</u>

The majority of the Group's sales of products were mainly made on the payment-in-advance basis or granted with credit periods ranging from 30 to 180 days. The Group seeks to maintain strict control over its outstanding receivables and has a credit control department to minimise credit risk. Overdue balances are reviewed regularly by senior management. There is a certain concentration of credit risk. The total trade receivables from the five largest debtors at 31 December 2025 represented 34.3% (2024: 38.7%) of the total trade receivables, while 17.8% (2024: 19.7%) of the total trade receivables was due from the largest debtor.

The Group does not hold any collateral or other credit enhancement over its trade receivable balances. Trade receivables are non-interest-bearing.

The ageing analysis of the trade receivables as at the end of the reporting period, based on the invoice date and net of loss allowance for impairment of trade receivables, is as follows:

	<b>2025</b>	2024
	<b>RMB'000</b>	RMB'000
Within 1 month	<b>390,888</b>	392,336
1 to 2 months	<b>17,593</b>	47,932
2 to 3 months	<b>21,352</b>	19,592
Over 3 months	<u><b>22,721</b></u>	<u>24,416</u>
Total	<u><b>452,554</b></u>	<u>484,276</u>

## 12. TRADE PAYABLES

An ageing analysis of the trade payables as at the end of the reporting period, based on the invoice date, is as follows:

	2025 <i>RMB'000</i>	2024 <i>RMB'000</i>
Within 1 month	104,987	438,723
1 to 2 months	285,584	143,770
2 to 3 months	204,124	5,761
Over 3 months	61,518	6,929
	<u>656,213</u>	<u>595,183</u>
Total	<u>656,213</u>	<u>595,183</u>

Included in the trade payables are trade payables of RMB135,000 (2024: RMB58,000) due to an associate which are repayable within 60 days, which represents credit terms similar to those offered by the associate to its major customers.

Trade payables are non-interest-bearing and are normally settled on terms of 60-days.

## 13. OTHER PAYABLES AND ACCRUALS

	2025 <i>RMB'000</i>	2024 <i>RMB'000</i>
Contract liabilities	53,019	32,433
Other payables	36,592	13,586
Accruals	31,847	49,432
Dividend payables	–	82,628
Lease liabilities	85,209	23,399
	<u>206,667</u>	<u>201,478</u>
Less: other payables included in non-current liabilities	<u>(65,400)</u>	<u>(13,167)</u>
Total	<u>141,267</u>	<u>188,311</u>

## 14. SHARE CAPITAL

	2025 <i>RMB'000</i>	2024 <i>RMB'000</i>
Authorised:		
3,000,000,000 ordinary shares of US\$0.0005 each (2024: 3,000,000,000 ordinary shares of US\$0.0005 each)	<u>10,280</u>	<u>10,280</u>
Issued and fully paid:		
1,621,488,096 ordinary shares of US\$0.0005 each ( <i>note b</i> ) (2024: 1,625,508,096 ordinary shares of US\$0.0005 each)	<u>5,589</u>	<u>5,603</u>

The movements in the Company's issued share capital during the year ended 31 December 2025 and 2024 were as follows:

	<b>Number of ordinary shares</b>	<b>Nominal value of ordinary shares US\$'000</b>	<b>Equivalent to RMB'000</b>
At 1 January 2024	1,354,590,080	678	4,637
Placement of new shares ( <i>note a</i> )	<u>270,918,016</u>	<u>141</u>	<u>966</u>
At 31 December 2024 and 1 January 2025	1,625,508,096	819	5,603
Share repurchase and cancellation ( <i>note b</i> )	<u>(4,020,000)</u>	<u>(2)</u>	<u>(14)</u>
At 31 December 2025	<u><u>1,621,488,096</u></u>	<u><u>817</u></u>	<u><u>5,589</u></u>

*Notes:*

- (a) On 25 June 2024, the Company and a placing agent entered into a placing agreement pursuant to which the Company has conditionally agreed to place a maximum of 270,918,016 placing shares to independent investors at a price of HK\$0.7 per share. The placing was completed on 24 July 2024 pursuant to which the Company has allotted and issued 270,918,016 placing shares. The net proceeds derived from the placing amounted to approximately HK\$189,453,000 (equivalent to RMB173,142,000) and resulted in the increase in share capital of approximately HK\$1,057,000 (equivalent to RMB966,000) and share premium of approximately HK\$188,396,000 (equivalent to RMB172,176,000, net of transaction costs of approximately HK\$190,000 (equivalent to RMB175,000).
- (b) During the year ended 31 December 2025, the Company repurchased 20,534,000 (2024: nil) of its own ordinary shares from the market at an aggregate consideration of RMB101,006,000 (2024: nil), of which 4,020,000 (2024: nil) were cancelled and 16,514,000 (2024: nil) were held as treasury shares. The movements in the Company's treasury share during the year ended 31 December 2025 and 2024 were as follows:

	<i>Note</i>	<b>Number of shares</b>	<i>RMB'000</i>
As at 1 January 2024, 31 December 2024 and 1 January 2025		–	–
Repurchased	(a)	20,534,000	101,006
Cancelled	(a)	<u>(4,020,000)</u>	<u>(8,155)</u>
As at 31 December 2025		<u><u>16,514,000</u></u>	<u><u>92,851</u></u>

*Note:*

- (a) During the year, the Company repurchased an aggregate of 20,534,000 Ordinary Shares, of which 4,020,000 were cancelled and 16,514,000 were held as treasury shares.

## MANAGEMENT DISCUSSION AND ANALYSIS

### BUSINESS OVERVIEW

The Group is a leading distributor of IVD products in the People's Republic of China ("PRC"). The Group is also engaged in the research, development, manufacturing and sales of its self-branded IVD products. The Group has been able to increase its market share and profits steadily by taking advantage of its competitive and diverse product portfolio, extensive distribution network and hospital coverage.

During the Reporting Period, the Group recorded a revenue of RMB2,820,663 thousand, representing a decrease of 10.8% as compared to the corresponding period of 2024. The Group's profit for the year decreased by 85.9% to RMB37,406 thousand for the Reporting Period.

### Business Segments

The Group's business can be broadly categorised into the following three segments:

- ***Distribution Business***

The distribution of IVD products forms the cornerstone of the Group's business. It primarily involves the trading of IVD analysers, reagents and other consumables to customers such as distributors, hospitals and healthcare institutions and logistics providers. The Group's distribution of IVD products was primarily conducted through Vastec Medical Equipment (Shanghai) Co., Ltd. ("**Vastec**"), a subsidiary of the Company. Vastec is primarily engaged in the distribution of Sysmex Corporation's ("**Sysmex**") haemostasis products in the PRC, it has been the sole national distributor of Sysmex's haemostasis products with exclusive distribution rights in the PRC since 1997. It also procures a diversified portfolio of IVD products from other leading international brands for distribution in the PRC. As of 31 December 2025, 6,553 of Sysmex haemostasis analysers have been installed by the Group and in use at hospitals and healthcare institutions accumulatively.

Having worked together for 28 years, Vastec and Sysmex Shanghai Ltd. continue to deepen their cooperative relationship. In the Reporting Period, they jointly respond to the dynamic demands of the medical device market in the PRC, further consolidating Vastec's market position as the exclusive distributor of Sysmex's haemostasis products in Chinese Mainland, and also providing a robust business foundation for the Group in a regulatory environment characterized by changing policies.

The Group also provides 4 Thrombotic Markers products manufactured by Sysmex to the market. These products adopt highly sensitive chemiluminescence technology, which may facilitate early diagnosis of thrombosis and fibrinolysis. As of 31 December 2025, 96 Sysmex' haemostasis immunoassay analysers which performed the 4 Thrombotic Markers have been installed by the Group at the hospitals and healthcare institutions in the PRC.

In addition, the Group provides solution services to the clinical laboratories of hospitals. This has enabled the Group to establish and maintain direct relationships with local medical practitioners so as to keep the Group close to the frontline of medical practice and market demand of IVD products. In 2025, the Group provided solution services to ten Class III or Class II hospitals in the PRC. Solution services contributed revenue of RMB248,531 thousand for the Reporting Period, representing an increase of 3.8% as compared to RMB239,381 thousand for the year ended 31 December 2024.

Through years of operations, the Group has established an expansive distribution network across 31 provinces, municipalities and autonomous regions in the PRC with an extensive hospital coverage. As of 31 December 2025, the Group had 297 direct customers, including hospitals and healthcare institutions, and 1,373 distributors in its established distribution network. As of 31 December 2025, the Group also covered 1,744 Class III hospitals mainly through its sub-distribution networks in the PRC, which further enhanced the competitiveness of the Group.

- ***After-sales Services***

Apart from distributing IVD products in the PRC, the Group also derives its revenue from providing after-sales services to end customers of Sysmex's haemostasis analysers in the PRC. In 2017, Vastec entered into an after-sales services agreement with Sysmex to provide after-sales services to haemostasis analysers procured by its end customers. The after-sales services provided by Vastec generally include maintenance and repair services, installation services and end customer trainings. Vastec primarily provides its after-sales services to hospitals and healthcare institutions. During the Reporting Period, the after-sales services business has been sustainably and steadily developing.

- ***Self-branded Products Business***

The Group has also engaged in the research, development, manufacturing and sales of IVD analysers and reagents under its own brand. The Group's self-branded IVD reagents were manufactured by Suzhou DiagVita Biotechnology Co., Ltd. and Bazoe Medical Co., Ltd., and the Group's IVD analysers were produced by the Group's equipment manufacturer, Langmai Biotechnology (Shandong) Co., Ltd. These self-developed IVD products primarily include IVD analysers and reagents under the IVD testing category of point-of-care testing, mass spectrometry and microbiology.

## **INDUSTRY OVERVIEW**

The continual growth of the healthcare market in the PRC is driven by a combination of favourable socio-economic factors including (i) the growth of the PRC population's disposable income and spending on healthcare, (ii) the increase of the overall PRC population and the accelerated ageing population, (iii) the expansion of the PRC economy, and (iv) strong support from the PRC government on healthcare spending as well as on continuous technological innovation. The Group expects that there will be significant growth potential for the healthcare market, especially the medical device market in the PRC. The integrated distribution value chain of the Group will provide strong support for the Group's development in the future.

According to Frost & Sullivan, by 2027, the PRC IVD market at ex-factory price level is projected to reach RMB278.7 billion with a compound annual growth rate of 15.7% during 2021 to 2027. In the future, the PRC IVD market is expected to grow with the aggravating trend of an ageing population, the growth of medical expenses per capita and the progress of technological development. The haemostasis analysis and other segmented fields are expected to continue to maintain a highly concentrated competitive landscape.

At the same time, global artificial intelligence technology is accelerating its penetration into the real economy, giving rise to disruptive innovations across multiple fields. AI-driven robotic technology has become a key engine for driving industrial upgrades, with application scenarios covering intelligent manufacturing, logistics automation, service interaction, and high-end equipment operation and maintenance, demonstrating cross-industry commercialization potential. The versatility of such technologies enables them to quickly adapt to diverse scenario requirements, becoming an emerging growth pole independent of traditional industries. The Group closely monitors the reshaping effects of such technological breakthroughs on the global industrial landscape and continuously evaluates their commercialization pathways in different verticals to explore the possibilities of expanding future business boundaries.

## **BUSINESS OUTLOOK AND DEVELOPMENT STRATEGIES**

On 12 July 2019, the Company successfully commenced its listing on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"), providing the Group with a good opportunity for further development. Based on continuous insights into technological innovations and market demands in the healthcare industry, the Group will further expand the boundaries of technological innovation while consolidating its core IVD business, actively exploring the strategic value of robotic technology and cutting-edge technologies to seize growth opportunities brought about by global technological changes.

Looking ahead, the Group will leverage the capital market to continue consolidating its leading position in the IVD industry in the PRC and adopt active development strategies, including but not limited to the following key directions:

## **Expanding product portfolio, the reach of distribution network and hospital coverage**

To capitalise on the high growth potential in the IVD market, the Group aims to continuously expand its product portfolio by diversifying product categories, increasing brand coverage, and expanding the breadth of its distribution network and hospital coverage. To achieve these purposes, the Group intends to (i) establish and maintain relationships with well-known IVD manufacturers and suppliers by way of stocking sufficient target IVD products to secure more distribution rights; (ii) strengthen its relationship with hospitals in urban areas, community clinics at the provincial and municipal levels and other customers in rural areas; and (iii) establish a new department and hire more sales personnel to manage the expansion of its distribution coverage.

## **Enhancing the intelligence of its solution services to continue to develop its distribution business**

The Group has been providing solution services to hospitals in the PRC since 2013. By being the general supplier of the clinical laboratory department in such hospitals, the Group participates in the design of laboratory layouts, provides centralised procurement of IVD products, conducts real-time inventory monitoring and provides other after-sales services to clinical laboratories. Through years of operation, the Group has accumulated a wealth of operational experience and a diversified product portfolio, thus being able to promote the same to other hospitals and healthcare institutions.

The Group plans to further upgrade the technical architecture of providing solution services to hospitals by introducing data-driven operational models and automated process management tools to enhance the operational efficiency and service response capability of clinical laboratories. Including but not limited to, optimizing inventory monitoring systems using intelligent algorithms to achieve precise demand forecasting; or enhancing real-time collaboration capabilities with medical institutions through remote diagnostic platforms. Such innovative initiatives will create higher added value for customers and provide technical support for the Group to explore the mid to high-end market.

The Group plans to hire more sales personnel to manage the promotion and marketing of solution services of the Group and to stock sufficient IVD products of various brands to strengthen the Group's advantages in centralized procurement. In addition, the Group intends to continuously participate in national and local IVD symposiums and academic conferences to enhance brand awareness.

## **Accelerating the upgrading of research and development capabilities to promote the strategic integration of intelligent hardware and automation technology**

Strong research and development capabilities are critical to securing future development and sustainable growth of the Group. The Group will continue to increase its investment in research and development, focusing on advancing technological breakthroughs in the fields of mass spectrometry, molecular diagnostics, and microbiology. The Group, in addition to actively considering further strengthening its technological reserves and research and development capabilities through equity acquisitions or additional investments in non-wholly owned subsidiaries or other local companies focusing on the research and development of

mass spectrometry reagents, also plans to further adopt artificial intelligence (“AI”) in its operations to enhance the development of the Group’s IVD products. AI-driven tools and analyzes can provide valuable insights in assisting the research, testing, and data analysis of the Group’s IVD product portfolio.

Meanwhile, the Group is also actively exploring the application potential of intelligent hardware development and high-precision sensing technology, including but not limited to the application potential of AI robotics technology in industrial automation, precision operations, and complex scenario services. The Group is committed to seeking companies focused on AI robotic solutions and intends to develop its AI robotics business through collaboration and capital increase, aiming to support the large-scale deployment of AI technology in the future, which marks an important step in the Group’s strategic layout in the field of AI.

### **Acquisition of the B-Soft Co., Ltd. and the synergies of the acquisition**

Reference is made to the announcement of the Company dated 16 November 2025 and 11 March 2026 in relation to the acquisition and the entrustment arrangement of B-Soft Co., Ltd. (the “**Target Company**” or “**B-Soft**”). On 12 November 2025, Hangzhou Better Smart Investment Management Consulting Partnership (Limited Partnership) Partnership)\* (杭州更好智投资管理諮詢合夥企業(有限合夥)) (the “**Purchaser**”), a subsidiary of the Company, entered into the share transfer agreement on 12 November 2025 with Mr. Ge Hang (the “**Vendor**”) (the “**Share Transfer Agreement**”), pursuant to which the Purchaser has conditionally agreed to acquire, and the Vendor has conditionally agreed to sell 96,525,096 A shares of the Target Company, representing 6.23% of the total issued share capital of the Target Company as at the date of the Share Transfer Agreement, at a Consideration of RMB500,000,000 (the “**Acquisition**”). On the same day, the Purchaser entered into the first voting rights entrusted agreement with the Vendor on 12 November 2025, pursuant to which the Vendor has agreed to entrust its voting rights attached to 155,780,282 A shares (including the Target Shares) of the Target Company, representing 10.66% of the total issued share capital of the Target Company as at the date hereof, to the Purchaser with effect from 12 November 2025. On 14 November 2025, the Purchaser and Jinfuyuan (Hainan) Private Equity Fund Management Partnership (Limited Partnership)\* (錦福源(海南)私募基金管理合夥企業(有限合夥)) (the “**Private Fund**”) has entered into the second voting rights entrusted agreement on 14 November 2025, pursuant to which the Private Fund has agreed to entrust its voting rights attached to 40,000,000 A shares of the Target Company, representing 2.58% of the total issued share capital of the Target Company as at the date hereof, to the Purchaser with effect from 14 November 2025 (the “**Entrustment Arrangement**”). Completion of the Acquisition has taken place on 6 February 2026. Immediately following completion of the Acquisition and as at the effective date of the Entrustment Arrangement, the Purchaser held voting rights of an aggregate of 195,780,282 A shares of the Target Company, representing 12.64% of the total issued share capital of the Target Company. The Purchaser will also be entitled to nominate a majority of the board of directors of the Target Company, and appoint its chairman and legal representative upon completion of the Acquisition. Accordingly, the Target Company will become a subsidiary of the Company, and the financial results of the Target Group will be consolidated into the Group’s consolidated financial statements. As one or more of the applicable percentage ratios exceed 25% but are less than 100%, and therefore the Acquisition constitutes a major transaction under Chapter 14 of the Listing Rules and is subject to the reporting, announcement, circular and the shareholders of the Company approval.

The Acquisition can create clear, actionable and commercially grounded synergies expected to enhance the combined Group's value. These synergies arise from the complementary business models, data assets, market presence and ecosystem positioning of the Group and B-Soft.

**(i) *Business Complementarity and Integration***

The Group's core business in in-vitro diagnostics ("IVD") products and its extensive distribution network are highly complementary to B-Soft's strength in healthcare information technology ("HIT"). This combination enables the creation of integrated diagnostic-clinical management solutions. Specifically, the Company's diagnostic data can be seamlessly interfaced with B-Soft's clinical systems to form a closed-loop data ecosystem. This integration is expected to increase customer retention, create significant cross-selling opportunities.

**(ii) *Data and Algorithm Empowerment***

B-Soft possesses a vast repository of structured clinical data accumulated from serving approximately 7,000 medical institutions. This dataset provides an unparalleled foundation for training, validating, and iterating the Group's proprietary AI algorithms related to diagnostic support and clinical pathway optimization. Conversely, the Group's advanced AI capabilities can be embedded into B-Soft's existing and future product suites, elevating their intelligence, functionality, and market competitiveness. This bidirectional empowerment is designed to accelerate the development of a leading "clinical intelligence platform" covering the full patient journey from diagnosis to treatment.

**(iii) *Channel and Network***

The Group's established IVD distribution network, which covers over 1,700 tertiary hospitals in the PRC, presents a direct channel for the rapid commercialization and deployment of B-Soft's AI-driven HIT solutions. Conversely, B-Soft's nationwide presence through more than 40 branches provides additional touchpoints for promoting the Group's IVD diagnostic products. This channel synergy is expected to reduce customer acquisition costs, accelerate market penetration for both product lines, and drive revenue growth.

**(iv) *R&D and Innovation***

Both entities have established partnerships with leading academic institutions, such as Zhejiang University. The integration will facilitate the consolidation of R&D efforts, shared access to research partnerships, and collaborative development of next-generation IVD and AI+healthcare technologies. This combined innovation engine aims to strengthen the Group's long-term intellectual property portfolio and sustain its technological leadership.

**(v) Capital and Ecosystem**

Upon consolidation, B-Soft will be integrated into the Group’s “IVD Ecosystem”, which represents the Group’s existing operating and deployment framework for hospital customers, rather than a standalone new business or platform. The IVD Ecosystem is designed to organise and coordinate the Group’s IVD products, healthcare information technology solutions and related AI-enabled applications in a structured manner when serving public medical institutions. Within this framework, B-Soft will serve as the core healthcare information technology and hospital information system layer, through which clinical workflows, laboratory processes and data standards are managed at hospital level. As hospitals typically rely on their existing information systems as the primary interface for adopting new diagnostic tools and digital solutions, B-Soft’s systems function as the essential integration layer that enables the Group’s IVD products and AI applications to be embedded into routine clinical and management workflows. Accordingly, B-Soft plays a central and non-substitutable role within the IVD Ecosystem by providing the system-level infrastructure through which other portfolio companies’ products and solutions are implemented, connected and scaled across hospital customers. Other portfolio companies within the ecosystem primarily contribute complementary technologies or products, while B-Soft provides the platform through which such technologies are operationalised in clinical settings.

Through this integration, the Group expects to improve operation efficiency, enhance customer stickiness and facilitate scalable deployment across its hospital network. In parallel, B-Soft is expected to benefit from coordinated access to the Group’s technical resources, distribution channels and customer base. For AI products that subsequently achieve stable cash flow generation, the Group’s intellectual property securitisation capabilities may be utilised as an additional financing tool to support further development, subject to market conditions.

The Group expects B-Soft to continue to play an important role in supporting the Group’s hospital information technology and digital healthcare service offerings. Building on its existing business foundation, B-Soft is expected to contribute to the Group’s broader ecosystem through closer coordination with other business units and the enhancement of operational capabilities.

In order to manage integration risks and support the sustainable development of the acquired businesses, B-Soft will systematically implement a post-investment management system for acquisition targets to promote deep resource integration and maximize synergies. It will enhance overall operational efficiency through multi-dimensional resource allocation, including research and innovation, production optimization, talent development, market channel sharing, technology integration, and financial standardization. At the same time, B-Soft will focus on accumulating management experience and optimizing systems, strengthening risk control mechanisms to ensure the sustainable development capabilities of the acquired companies, effectively manage potential risks of goodwill impairment, and build a management support system for stable growth in subsequent operations. The Company considers to increase its shareholdings in B-Soft through placing or other corporate actions in the future. Further announcement will be made by the Company as and when appropriate in accordance with the Listing Rules.

## FINANCIAL REVIEW

### Overview

The financial summary set out below is extracted or calculated from the audited consolidated financial statements of the Group for the Reporting Period which were prepared in accordance with International Financial Reporting Standards.

During the Reporting Period, the Group recorded revenue of RMB2,820,663 thousand, representing a decrease of RMB341,752 thousand or 10.8% as compared to the corresponding period of 2024.

During the Reporting Period, the Group recorded a net profit for the year of RMB37,406 thousand, representing a decrease of RMB228,628 thousand or 85.9% as compared to the corresponding period of 2024. Profit attributable to owners of the parent amounted to RMB34,933 thousand, representing a decrease of RMB225,487 thousand or 86.6% as compared to the corresponding period of 2024.

During the Reporting Period, the Group recorded non-GAAP adjusted profit for the year of RMB52,409 thousand, representing a decrease of RMB228,004 thousand or 81.3% as compared to the corresponding period of 2024.

	For the year ended 31 December		Change
	2025 RMB'000	2024 RMB'000	
<b>Operating Results</b>			
Revenue	2,820,663	3,162,415	(10.8%)
Gross profit	566,370	751,173	(24.6%)
Earnings before interest and depreciation and amortization (EBITDA)	203,708	475,956	(57.2%)
Profit attributable to owners of the parent	34,933	260,420	(86.6%)
Adjusted profit for the year (Note 1)	52,409	280,413	(81.3%)
Adjusted profit attributable to owners of the parent (Note 1)	49,679	274,246	(81.9%)
<b>Financial Ratios</b>			
Gross profit margin (%) (Note 2)	20.1%	23.8%	(3.7%)
Net profit margin (%) (Note 2)	1.3%	8.4%	(7.1%)
Adjusted profit for the year margin (%) (Note 3)	1.9%	8.9%	(7.0%)
Return on assets (%) (Note 2)	0.7%	5.2%	(4.5%)
Return on equity (%) (Note 2)	1.0%	7.4%	(6.4%)
Average turnover days of trade receivables (days) (Note 2)	61	59	2
Average turnover days of inventories (days) (Note 2)	285	178	107
Average turnover days of trade payables (days) (Note 2)	101	83	18

	<b>31 December</b>		
	<b>2025</b>	2024	Change %
	<i>RMB'000</i>	<i>RMB'000</i>	
<b>Financial Position</b>			
Total assets	<b>5,935,217</b>	5,523,884	7.4%
Equity attributable to owners of the parent	<b>2,947,700</b>	3,714,618	(20.6%)
Cash and cash equivalents	<b>350,924</b>	1,774,358	(80.2%)
	<u><u>                    </u></u>	<u><u>                    </u></u>	<u><u>                    </u></u>
<b>Financial Ratios</b>			
Current ratio (times) <i>(Note 2)</i>	<b>1.3</b>	2.4	(1.1)
Quick ratio (times) <i>(Note 2)</i>	<b>0.5</b>	1.6	(1.1)
Debt to equity ratio (times) <i>(Note 2)</i>	<b>0.6</b>	0.2	0.4
	<u><u>                    </u></u>	<u><u>                    </u></u>	<u><u>                    </u></u>

*Note 1:* Adjusted profit for the year and adjusted profit attributable to owners of the parent are non-GAAP financial measures. See also the paragraph headed “Adjusted profit for the year” in this announcement for more information.

*Note 2:* Gross profit margin equals gross profit divided by revenue.

Net profit margin equals net profit divided by revenue.

Return on assets equals net profit divided by average total assets during the reporting period.

Return on equity equals net profit attributable to owner of the Company divided by average equity attributable to owner of the Company during the reporting period.

Average turnover days of trade receivables equal to the average of the opening and closing balances of trade receivables of the reporting period divided by revenue and multiplied by 365 days.

Average turnover days of inventories equal to the average of the opening and closing balances of inventories of the reporting period divided by cost of sales and multiplied by 365 days.

Average turnover days of trade payables equal to the average of the opening and closing balances of trade payables of the reporting period divided by cost of sales and multiplied by 365 days.

Current ratio equals total current assets divided by total current liabilities as at the end of the reporting period.

Quick ratio equals total current assets less inventories divided by total current liabilities as at the end of the reporting period.

Debt to equity ratio equals total debt divided by total equity as at the end of the reporting period. Debt means interest-bearing borrowings.

*Note 3:* Adjusted profit for the year margin is a financial ratio and is calculated by adjusted profit for the year (see Note 1 above), a non-GAAP financial measures, divided by the revenue for the year.

## Revenue

Revenue of the Group amounted to RMB2,820,663 thousand for the Reporting Period, representing a decrease of 10.8% as compared to RMB3,162,415 thousand for the year ended 31 December 2024. Such decrease was primarily due to a more competitive operating environment in the IVD industry.

### *Revenue by business segment*

The table below sets out the breakdown of the Group's revenue by business segment for the years indicated:

Business segment	For the year ended 31 December				Change
	2025		2024		
	<i>RMB'000</i>	<i>% of total</i>	<i>RMB'000</i>	<i>% of total</i>	
Distribution business	2,638,797	93.6	2,946,782	93.2	(10.5%)
After-sales services	172,543	6.1	205,989	6.5	(16.2%)
Self-branded products business	9,323	0.3	9,644	0.3	(3.3%)
Total	<u>2,820,663</u>	<u>100.0</u>	<u>3,162,415</u>	<u>100.0</u>	<u>(10.8%)</u>

### *Revenue by product type*

The table below sets out the breakdown of the Group's revenue generated from distribution business and self-branded products business by product type for the years indicated:

Product type	For the year ended 31 December				Change
	2025		2024		
	<i>RMB'000</i>	<i>% of total</i>	<i>RMB'000</i>	<i>% of total</i>	
IVD analysers					
– Distribution business	334,091	12.6	304,658	10.3	9.7%
– Self-branded products business	1,876	0.1	1,821	0.1	3.0%
Subtotal	<u>335,967</u>	<u>12.7</u>	<u>306,479</u>	<u>10.4</u>	<u>9.6%</u>
IVD reagents and other consumables					
– Distribution business	2,304,706	87.0	2,642,124	89.3	(12.8%)
– Self-branded products business	7,447	0.3	7,823	0.3	(4.8%)
Subtotal	<u>2,312,153</u>	<u>87.3</u>	<u>2,649,947</u>	<u>89.6</u>	<u>(12.7%)</u>
Total	<u>2,648,120</u>	<u>100.0</u>	<u>2,956,426</u>	<u>100.0</u>	<u>(10.4%)</u>

## Revenue by channel

The table below sets out the breakdown of the Group's revenue generated from distribution business and self-branded products business by sales channels for the years indicated:

Sales channel	For the year ended 31 December				Change
	2025		2024		
	<i>RMB'000</i>	<i>% of total</i>	<i>RMB'000</i>	<i>% of total</i>	
Distribution business					
– Distributors	2,083,824	78.7	2,374,583	80.4	(12.2%)
– Hospitals and healthcare institutions	386,257	14.6	391,676	13.2	(1.4%)
– Logistics providers	168,716	6.4	180,523	6.1	(6.5%)
Subtotal	<u>2,638,797</u>	<u>99.7</u>	<u>2,946,782</u>	<u>99.7</u>	<u>(10.5%)</u>
Self-branded products business					
– Distributors	8,795	0.3	9,096	0.3	(3.3%)
– Hospitals and healthcare institutions	528	0.0	548	0.0	(3.6%)
Subtotal	<u>9,323</u>	<u>0.3</u>	<u>9,644</u>	<u>0.3</u>	<u>(3.3%)</u>
Total	<u><u>2,648,120</u></u>	<u><u>100.0</u></u>	<u><u>2,956,426</u></u>	<u><u>100.0</u></u>	<u><u>(10.4%)</u></u>

## Cost of sales

Cost of sales of the Group amounted to RMB2,254,293 thousand for the Reporting Period, representing a decrease of 6.5% as compared to RMB2,411,242 thousand for the year ended 31 December 2024. Such decrease was primarily due to the decrease in revenue.

## Cost of sales by business segment

The table below sets out the breakdown of the Group's cost of sales by business segment for the years indicated:

Business segment	For the year ended 31 December				Change
	2025		2024		
	<i>RMB'000</i>	<i>% of total</i>	<i>RMB'000</i>	<i>% of total</i>	
Distribution business	2,157,834	95.7	2,318,979	96.2	(6.9%)
After-sales services	93,463	4.2	89,281	3.7	4.7%
Self-branded products business	2,996	0.1	2,982	0.1	0.5%
Total	<u><u>2,254,293</u></u>	<u><u>100.0</u></u>	<u><u>2,411,242</u></u>	<u><u>100.0</u></u>	<u><u>(6.5%)</u></u>

### ***Cost of sales by product type***

The table below sets out the breakdown of the Group's cost of sales for distribution business and self-branded products business by product type for the years indicated:

Product type	For the year ended 31 December				Change
	2025		2024		
	<i>RMB'000</i>	<i>% of total</i>	<i>RMB'000</i>	<i>% of total</i>	
IVD analysers					
– Distribution business	297,519	13.8	236,222	10.2	25.9%
– Self-branded products business	700	0.0	815	0.0	(14.1%)
Subtotal	298,219	13.8	237,037	10.2	25.8%
IVD reagents and other consumables					
– Distribution business	1,860,315	86.1	2,082,756	89.7	(10.7%)
– Self-branded products business	2,296	0.1	2,168	0.1	5.9%
Subtotal	1,862,611	86.2	2,084,924	89.8	(10.7%)
Total	2,160,830	100.0	2,321,961	100.0	(6.9%)

### **Gross profit and gross profit margin**

Gross profit represents revenue less cost of sales. Gross profit of the Group amounted to RMB566,370 thousand for the Reporting Period, representing a decrease of 24.6% as compared to RMB751,173 thousand for the year ended 31 December 2024. Such decrease was primarily attributable to i) the decrease in revenue; ii) a lower price to adapt to more competitive IVD market.

Gross profit margin is calculated as gross profit divided by revenue. Gross profit margin of the Group was 20.1% for the Reporting Period, which decreased from 23.8% for the year ended 31 December 2024. The decrease was primarily attributable to lower price to adapt to more competitive IVD market.

### ***Gross profit and gross profit margin by business segment***

The table below sets out the breakdown of the Group's gross profit and gross profit margin by business segment for the years indicated:

Business segment	For the year ended 31 December				Change
	2025		2024		
	Gross profit <i>RMB'000</i>	Gross profit margin %	Gross profit <i>RMB'000</i>	Gross profit margin %	
Distribution business					
– IVD reagents and other consumables	<b>444,391</b>	<b>19.3</b>	559,368	21.2	(20.6%)
– IVD analysers	<b>36,572</b>	<b>10.9</b>	68,436	22.5	(46.6%)
Subtotal	<b>480,963</b>	<b>18.2</b>	627,804	21.3	(23.4%)
After-sales services	<b>79,080</b>	<b>45.8</b>	116,708	56.7	(32.2%)
Self-branded products business					
– IVD reagents and other consumables	<b>5,151</b>	<b>69.2</b>	5,655	72.3	(8.9%)
– IVD analysers	<b>1,176</b>	<b>62.7</b>	1,006	55.2	16.9%
Subtotal	<b>6,327</b>	<b>67.9</b>	6,661	69.1	(5.0%)
Total	<b>566,370</b>	<b>20.1</b>	751,173	23.8	(24.6%)

### ***Gross profit and gross profit margin by product type***

The table below sets out the breakdown of the Group's gross profit and gross profit margin generated from distribution business and self-branded products business by product type for the years indicated:

Product type	For the year ended 31 December				Change
	2025		2024		
	Gross profit RMB'000	Gross profit margin %	Gross profit RMB'000	Gross profit margin %	
IVD analysers					
– Distribution business	36,572	10.9	68,436	22.5	(46.6%)
– Self-branded products business	1,176	62.7	1,006	55.2	16.9%
Subtotal	<u>37,748</u>	<u>11.2</u>	<u>69,442</u>	<u>22.7</u>	<u>(45.6%)</u>
IVD reagents and other consumables					
– Distribution business	444,391	19.3	559,368	21.2	(20.6%)
– Self-branded products business	5,151	69.2	5,655	72.3	(8.9%)
Subtotal	<u>449,542</u>	<u>19.4</u>	<u>565,023</u>	<u>21.3</u>	<u>(20.4%)</u>
Total	<u><u>487,290</u></u>	<u><u>18.4</u></u>	<u><u>634,465</u></u>	<u><u>21.5</u></u>	<u><u>(23.2%)</u></u>

## Other income and (losses) gains, net

Other income and losses, net of the Group amounted the losses of RMB5,203 thousand for the Reporting Period, representing a decrease of 123.9% as compared to RMB21,813 thousand for the year ended 31 December 2024. Such decrease was primarily due to the decrease in foreign exchange gain.

	For the year ended	
	31 December	
	2025	2024
	RMB'000	RMB'000
<b>Other income</b>		
Bank interest income	1,830	2,672
Rental income	95	350
Government subsidies	19,659	15,524
Others	9,374	1,635
	<hr/>	<hr/>
Total other income	30,958	20,181
	<hr/>	<hr/>
<b>Gains or losses</b>		
Written-off of prepayment	348	(143)
Gain (loss) on termination/modification of lease contracts	336	(66)
Gain on disposal of items of property, plant and equipment, net	29	47
Foreign exchange differences, net	(36,874)	1,794
	<hr/>	<hr/>
Total (losses) gains, net	(36,161)	1,632
	<hr/>	<hr/>
Total other income and (losses) gains, net	(5,203)	21,813
	<hr/> <hr/>	<hr/> <hr/>

## Selling and distribution expenses

Selling and distribution expenses of the Group amounted to RMB159,548 thousand for the Reporting Period, representing an increase of 14.1% as compared to RMB139,805 thousand for the year ended 31 December 2024. Such increase was primarily due to the increase of the technical service fees paid to a prospective partner, an IVD company with chemiluminescence technology and products as its core.

## Administrative expenses

Administrative expenses of the Group amounted to RMB220,912 thousand for the Reporting Period, representing an increase of 33.6% as compared to RMB165,332 thousand for the year ended 31 December 2024. Such increase was primarily due to the increase of the expenses incurred from the Group's newly launched AI business.

## **Finance costs**

Finance costs of the Group amounted to RMB60,687 thousand for the Reporting Period, representing an increase of 68.7% as compared to RMB35,979 thousand for the year ended 31 December 2024. Such increase was primarily due to the increase in average bank borrowing amount during the Reporting Period.

## **Profit for the year**

Profit of the Group for the year amounted to RMB37,406 thousand for the Reporting Period, representing a decrease of 85.9% as compared to RMB266,034 thousand for the year ended 31 December 2024. Such decrease was primarily attributable to i) the decrease in revenue; ii) the increase in expenses incurred from the Group's newly launched AI business and iii) the increase in finance costs.

## **Adjusted profit for the year**

Adjusted profit of the Group is a non-GAAP financial measure which excludes certain impact of non-operating items which affect the results presented in the consolidated financial statements but which the Company considers to be not indicative of the operating performance of the Group. Such non-GAAP measures are presented, with the intent to provide the Shareholders and potential investors with supplementary information to assess the performance of the Group's core operations. Adjusted profit for the year is calculated by deducting the items listed below from the profit for the year. Adjusted profit for the year amounted to RMB52,409 thousand for the Reporting Period, representing a decrease of 81.3% as compared to RMB280,413 thousand for the year ended 31 December 2024. Such increase was primarily attributable to i) the decrease in revenue; ii) the increase in expenses incurred from the Group's newly launched AI business and iii) the increase in finance cost.

	<b>2025</b>	2024
	<b>RMB'000</b>	RMB'000
Profit for the year	<b>37,406</b>	266,034
Adjusted for non-operating items:		
Fair value loss on financial assets at fair value through profit or loss	<b>11,264</b>	9,468
Share of loss/(profit) of a joint venture	<b>5,450</b>	8,612
Deferred tax on fair value adjustments of equity investments at fair value through profit or loss	<b>(1,711)</b>	(3,701)
Adjusted profit for the year (non-GAAP)	<b>52,409</b>	280,413

\* The aforementioned joint venture focuses on equity investment in IVD industry, see Company's announcement dated 3 August 2020.

\*\* Non-GAAP financial measure does not have a standardised meaning prescribed by GAAP and therefore may not be comparable to similar measures presented by other companies. Non-GAAP financial measure should be considered in addition to, not as a substitute for, measures of the Group's financial performance prepared in accordance with relevant GAAP.

### Use of proceeds from the placement of new shares under general mandate

The net proceeds from the placing of new shares under general mandate on 24 July 2024, after deducting the commissions and other fees and expenses in relation to the placing, amounted to approximately HK\$189.6 million. The Group had used the net proceeds as follows:

Intended uses of the net proceeds	Original allocation of net proceeds <i>HK\$ (million)</i>	Utilized during the Reporting Period <i>HK\$ (million)</i>	Utilized up to 31 December 2025 <i>HK\$ (million)</i>	Remaining balance of net proceeds as at 31 December 2025 <i>HK\$ (million)</i>
(A) Medical related business development				
(i) Acquisition of and/or investment in business(es) or cooperation with other companies	151.3	11.3	151.3	–
(ii) Support the research and development of biologic project products	18.9	12.2	16.1	2.8
	170.2	23.5	167.4	2.8
(B) General working capital of the Company	18.9	–	18.9	–
Total	189.1	23.5	186.3	2.8

There was no material change between the intended use and the actual use of the net proceeds. Unutilized net proceeds of approximately HK\$2.8 million is currently expected to be fully utilized within two years from the completion date of such share placement.

### **Liquidity and financial resources**

As of 31 December 2025, the Group had cash and cash equivalents of RMB350,924 thousand (primarily denominated in HK\$, RMB and US\$), as compared to RMB1,774,358 thousand as of 31 December 2024. The approach adopted by the Board to manage the liquidity of the Group is to ensure sufficient liquidity at any time to meet its matured liabilities as to avoid any unacceptable loss or damage to the Group's reputation.

### **Capital structure**

As of 31 December 2025, the Group's total equity attributable to owners of the parent was RMB2,947,700 thousand (31 December 2024: RMB3,714,618 thousand), comprising share capital of RMB5,589 thousand (31 December 2024: RMB5,603 thousand) and reserves of RMB2,942,111 thousand (31 December 2024: RMB3,709,015 thousand).

### **Net current assets**

The Group had net current assets of RMB913,764 thousand as of 31 December 2025, representing a decrease of RMB1,256,205 thousand as compared to RMB2,169,969 thousand as of 31 December 2024.

### **Interest rate risk**

The Group's exposure to the risk of changes in market interest rates primarily relates to its cash and bank balances. The Group has used interest rate swaps to hedge its interest rate risk, and hedged significant interest rate risk.

### **Foreign currency risk**

The Group faces transactional currency exposures arising from bank deposits held by operating units in currencies other than the units' functional currency. The currencies giving rise to such risk are primarily US\$ and HK\$. For the Reporting Period, the Group recorded a net foreign exchange loss of RMB36,874 thousand, as compared to a net foreign exchange gain of RMB1,794 thousand for the year ended 31 December 2024. The Group has assessed its foreign currency risk exposure and has entered into currency swap contact to mitigate foreign currency risk during the year and as at the reporting date.

## **Material asset valuation**

Management of the Company has engaged Colliers International (Hong Kong) Limited to perform the impairment assessment on the Distribution CGU (cash generating unit of distribution of IVD reagents and medical equipment) for the Reporting Period, which was based on value-in-use calculation using cash flow projections based on financial budgets covering a five-year period approved by senior management. The recoverable amount of the Distribution CGU has a significant headroom of not less than RMB100 million over the carrying amount of net assets of Distribution CGU. Management, based on the sensitivity analysis performed, is not aware of any possible change in key assumptions used that would cause a cash generating unit's carrying amount to exceed its recoverable amount.

## **Credit risk**

The Group trades only with recognised and creditworthy third parties. It is the Group's policy that all customers who wish to trade on credit terms are subject to credit verification procedures. In addition, receivable balances are monitored on an ongoing basis and Group's exposure to bad debts is not significant. For transactions that are not denominated in the functional currency of the relevant operating unit, the Group does not offer credit terms without the specific approval of the head of credit control.

## **Liquidity risk**

The Group's objective is to maintain a balance between continuity of funding and flexibility through the use of bank borrowings and projected cash flows from operations.

## **Capital expenditure**

For the Reporting Period, the Group's total capital expenditure amounted to RMB173,784 thousand, which was primarily used in purchase of property, plant and equipment and addition of right-of-use assets.

## **Charge/pledge of assets**

As of 31 December 2025, the Group's bank deposits of RMB197,758 thousand were pledged to secure the Group's letter of credit in the aggregate amount of RMB405,725 thousand and loan in the aggregate amount of RMB150,000 thousand.

## **Borrowings**

The Group had bank borrowings of RMB1,842,042 thousand as of 31 December 2025 denominated in RMB, which bore interest at fixed rates. All of the Group's bank borrowings as of 31 December 2025 were repayable on or before 31 December 2026.

## **Contingent liabilities and guarantees**

As of 31 December 2025, the Group did not have any material contingent liabilities, guarantees or litigation against it (as of 31 December 2024: nil).

## **Gearing ratio**

As of 31 December 2025, the Group's gearing ratio, which is equivalent to total debt divided by total assets, was 31.0% (as of 31 December 2024: 13.3%).

## **Significant investments and future plans for investment and capital assets**

As of 31 December 2025, the Group had a capital commitment to a joint venture of RMB28,835 thousand (as of 31 December 2024: RMB29,332 thousand). As of 31 December 2025, the Group did not hold any other significant investments in the equity interests of other companies. The Group does not have other plans for material investments and capital assets which have been authorised by the Board except as referred to in this announcement.

## **Final dividend**

The Board has resolved not to recommend a final dividend for the Reporting Period (2024: nil).

## **Employee and remuneration policy**

As of 31 December 2025, the Group had 910 employees (as of 31 December 2024: 863 employees). Total staff remuneration expenses, including remuneration for Directors, for the Reporting Period amounted to RMB221,730 thousand (2024: RMB221,693 thousand).

The Group has adopted a performance-based remuneration policy for its employees. Remuneration is determined with reference to performance, skills, qualifications and experience of the staff concerned and with reference to the Group's operating results and comparable market practices.

In addition to salary payments, other staff benefits include pension, social insurance and housing provident contribution made by the Group, performance-based compensation, bonus, share incentives through the Company's share option scheme and share award scheme. These share schemes provide flexibility to the Group in attracting and retaining personnel, and in providing incentive to employees in recognition of their contribution to the Group. As of 31 December 2025, there were 2,711,000 outstanding share options granted under the Company's share option scheme.

## **Notifiable transaction**

### **Acquisition of Shares in GoFintech Quantum Innovation Limited (Stock Code: 290)**

On 1 September 2025, the Company and Final Touch Ltd. (a wholly owned subsidiary of the Company) entered into a conditional sale and purchase agreement (the “**Sale and Purchase Agreement**”) with Dr. Liu Zhiwei, AI International Capital Management Ltd., Caitex Technology Holdings Limited and Mr. Wang Tao to acquire approximately 20.31% of the entire issued share capital of GoFintech Quantum Innovation Limited (stock code: 290) (the “**Acquisition**”). The consideration was to be satisfied by the allotment and issuance of 324,297,619 shares of the Company. However, as the conditions precedent to completion of the Acquisition were not fulfilled (or waived) on or before the long stop date (i.e. 31 October 2025), the Sale and Purchase Agreement was terminated; all rights, obligations and liabilities of the parties ceased and determined, and neither party has any claim against the other, save for any antecedent breaches of the Sale and Purchase Agreement. Please refer to the Company’s announcements dated 1 September 2025 and 31 October 2025 for details.

### **Proposed Specific Mandate for Potential Cryptocurrency Acquisitions**

On 15 August 2025, the Board proposed seeking Shareholders’ approval for a specific mandate to authorize and empower the Board to acquire Ether (ETH) through open market transactions on an ongoing basis, up to a total amount of HK\$3 billion. As additional time is required to obtain approval for this specific mandate at the extraordinary general meeting, the Board has decided not to proceed with the Application as of the date of this announcement. Please refer to the Company’s announcements dated 15 August 2025 and 31 October 2025 for details.

### **Acquisition of Shares in B – Soft Co., Ltd**

Please refer to Management Discussion & Analysis section headed “**Acquisition of the B-Soft Co., Ltd. and the synergies of the acquisition**” of this announcement, and the announcements of the Company dated 16 November 2025, and 11 March 2026 for further details.

### **Change of auditor**

Prism Hong Kong Limited was appointed as the Company’s auditor with effect from 20 February 2025, to fill the vacancy following the resignation of Moore CPA Limited which took effect on 17 February 2025. More information is set out in the Company’s announcements dated 17 February 2025, 20 February 2025, 11 March 2025 and 13 March 2025.

## **Change of company name and other corporate matters**

The Company's English name changed to "ETHK Labs Inc." with effect from 26 November 2025, and its English stock short name for trading in the Shares on the Stock Exchange became "ETHK LABS INC." since 30 January 2026. The Company's dual foreign name in Chinese and its Chinese stock short name remain unchanged. More information is set out in the Company's circular dated 6 June 2025.

The website of the Company changed from "http://www.ivdholding.com" to "https://ivd.xyz" with effect from 30 July 2025. More information is set out in the Company's announcement dated 30 July 2025.

## **Adoption of share scheme**

The Company adopted a new share award scheme with the approval of the shareholders with effect from 30 June 2025. The scheme intends to (i) incentivize and motivate eligible participants to contribute to the Group, optimise their performance and efficiency for the benefit of the Group, and achieve designated goals, (ii) encourage continuing commitment to the Group, (iii) attract important candidates to join the Group to facilitate the development of the Group; and (iv) recognise the contributions that eligible participants have or may have made or may make to the Group (whether directly or indirectly). More information is set out in the Company's circular dated 6 June 2025.

## **Change of composition of the Board and other personnel**

The following changes of the composition of the Board took place since 1 January 2025:

- (a) The following appointments/redesignation took place: Ms. Tai Yang appointed as an independent non-executive Director from 1 July 2025, and re-designated as an executive Director from 20 October 2025; Mr. Xu Da and Mr. Zhang Jianlei, appointed as independent non-executive Directors from 1 July 2025; Ms. Yi Xiao, appointed as an executive Director and the chief scientist of the Company from 6 February 2026. They have obtained the legal advice referred to in Rule 3.09D of the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**"), and each of them has confirmed he/she understood his/her obligations as a director of a listed issuer (For Ms. Tai, on 1 July 2025, For Mr. Xu, Mr. Zhang, on 1 July 2025 and for Ms. Yi, on 6 February 2026); and
- (b) The following retirements/resignations became effective: Mr. Ho Kuk Sing, retired as the chairman of the Board, an executive Director and chief executive officer from 1 July 2025; Dr. Leung Ka Sing, retired as an independent non-executive Director from 1 September 2025; Mr. Law Kim Fai, resigned as an executive Director, chief financial officer, company secretary, authorised representative under the Listing Rules and authorized representative under the Companies Ordinance from 13 January 2026; Ms. Tai Yang, resigned as an executive Director from 13 January 2026; Mr. Wong Sze Lok, resigned as an independent non-executive Director from 13 January 2026.

Corresponding changes were made to the composition of the Board committees. The list of Directors and their role and function dated 6 February 2026 sets out the composition of the Audit Committee, the Remuneration Committee and the Nomination Committee following such changes as of the date of this announcement.

Mr. Chan Siu Kei Ken (an executive Director) became the company secretary from 13 January 2026. Mr. Lin Xianya (an executive Director) become an authorised representative of the Company pursuant to the Listing Rules and an authorized representative of the Company under the Companies Ordinance from 13 January 2026.

More information with respect to the above and other associated changes in the Board committees and personnel is set out in the Company's announcements dated 30 June 2025, 29 August 2025, 20 October 2025, 21 October 2025, 13 January 2026 and 6 February 2026, respectively.

### **Subsequent events**

Save as referred to in this announcement, the Group did not have any material event which affected the Group significantly and required to be disclosed under the Listing Rules since the end of the Reporting Period and up to the date of this announcement.

## **SUPPLEMENTAL INFORMATION**

### **Review by the audit committee**

The Audit Committee has reviewed the Company's annual results for the Reporting Period and this announcement.

### **Scope of work of Prism Hong Kong Limited**

The figures in respect of the Group's consolidated statement of financial position, consolidated statement of profit or loss and other comprehensive income and the related notes thereto for the year ended 31 December 2024 as set out in the Preliminary Announcement have been agreed by the Group's auditors, Prism Hong Kong Limited, to the amounts set out in the Group's audited consolidated financial statements for the year. The work performed by Prism Hong Kong Limited in this respect did not constitute an assurance engagement in accordance with Hong Kong Standards on Auditing, Hong Kong Standards on Review Engagements or Hong Kong Standards on Assurance Engagements issued by the Hong Kong Institute of Certified Public Accountants and consequently no assurance has been expressed by Prism Hong Kong Limited on the preliminary announcement.

## **Purchase, sale or redemption of the Company's listed securities**

During the Reporting Period, the Company repurchased a total of 20,534,000 Shares at a total consideration of approximately HK\$110,783 thousand on the Stock Exchange (out of which (i) 4,020,000 Shares (repurchase with a total consideration of HK\$8,902 thousand) were repurchased pursuant to the general mandate granted to the Directors by ordinary resolution of the Shareholders at the annual general meeting of the Company held on 28 June 2024. These shares have been canceled as of the date of this announcement; and (ii) 16,514,000 Shares (repurchase with a total consideration of HK\$101,881 thousand) were repurchased pursuant to the general mandate granted to the Directors by ordinary resolution of the Shareholders at the annual general meeting of the Company held on 30 June 2025, and these 16,514,000 shares were repurchased and held as treasury shares). As of 31 December 2025, the Company held 16,514,000 treasury shares intended to satisfy awards or options under the Company's schemes, rather than issuing new shares of the Company, thereby reducing dilution. Please refer to Note 14 to the condensed consolidated financial information for more information.

Save as disclosed in this announcement, during the Reporting Period, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of its listed securities (including sale of treasury shares as defined under the Listing Rules).

## **Material acquisitions and disposals of subsidiaries, associates or joint ventures**

The Group did not have any material acquisition or disposal of subsidiaries, associates or joint ventures during the Reporting Period except as referred to in this announcement.

## **Compliance with the model code for securities transactions by directors**

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the “**Model Code**”) set out in Appendix C3 to the Listing Rules regarding securities transactions by the Directors.

All Directors have confirmed, following specific enquiries by the Company, that they have complied with the Model Code throughout the Reporting Period.

## **Compliance with the corporate governance code**

During the Reporting Period, save for the code provision addressed below, the Company has complied with the applicable code provisions as set out in Part 2 of Appendix C1 to the Listing Rules.

Code provision C.2.1 stipulates that the roles of chairman and chief executive should be separate and should not be performed by the same individual. The division of responsibilities between the chairman and chief executive should be clearly established and set out in writing. From 1 January 2025 to 1 July 2025, the chairman and chief executive officer of the Company was held by Mr. Ho Kuk Sing. Mr. Ho was one of the founders of the Group and has extensive experience in the industry. The Board is of the view that given that Mr. Ho had been responsible for leading the strategic planning and business development of the Group, the arrangement allowed for effective and efficient planning and implementation of business decisions and strategies under his leadership, which benefited the management and development of the Group's business. The Company does not have the position of chairman and chief executive following Mr. Ho's retirement on 1 July 2025. Major decisions are determined by the Board. The Company considers such arrangement is appropriate and reasonable in view of the Group's business and operation.

### **Public float**

From information publicly available to the Company and within the knowledge of the Directors, at least 25% of the Company's total issued shares (excluding treasury shares) were held by the public at all times during the Reporting Period in compliance with the applicable public float requirement under the Listing Rules.

### **Pre-emptive rights**

There are no provisions for pre-emptive rights under the Company's articles of association and the laws of the Cayman Islands, which would oblige the Company to offer new shares on a pro-rata basis to the existing shareholders of the Company.

### **Annual report and notice of annual general meeting**

The 2025 annual report containing information required by the Listing Rules and the notice of the forthcoming annual general meeting will be published on the websites of the Hong Kong Exchanges and Clearing Limited (<http://www.hkexnews.hk>) and the Company (<http://www.ivd.xyz.com>) in due course.

By Order of the Board  
**ETHK Labs Inc.**  
**Lin Xianya**  
*Executive Director*

Hong Kong, 27 March 2026

*As at the date of this announcement, the Board comprises three executive directors, namely, Mr. Lin Xianya, Mr. Chan Siu Kei Ken and Ms. Yi Xiao, two non-executive directors, namely, Ms. Yao Haiyun and Mr. Liu Fei and three independent non-executive directors, namely, Dr. Zhong Renqian, Mr. Xu Da and Mr. Zhang Jianlei.*

*Certain figures in this announcement have been subject to rounding adjustments.*

*This announcement may contain certain forward-looking statements that reflect the Company's beliefs, plans or expectations about the future. These statements are based on a number of assumptions, current estimates and projections, and subject to inherent risks, uncertainties and other factors which may or may not be beyond the Company's control. The actual outcomes may differ. Nothing contained in these statements is, or shall be, relied upon as any assurance, representation or warranty otherwise. Neither the Company nor its directors, staff, agents, advisers or representatives assume any responsibility to update, supplement, correct these statements or adapt them to future events.*